E
TCRT icon

Ergoteles’s Alaunos Therapeutics TCRT Stock Holding History

Ergoteles’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-761
Closed -$74.1K – 1743
2022
Q4 		$74.1K Sell
761
-2,475
-76% -$359K ﹤0.01% 1258
2022
Q3 		$835K Sell
3,236
-3,010
-48% -$874K 0.03% 561
2022
Q2 		$1.16M Buy
+6,246
New +$597K 0.03% 483
2021
Q4 		– Sell
-1,427
Closed -$389K – 1584
2021
Q3 		$389K Buy
1,427
+1,122
+368% +$343K 0.01% 693
2021
Q2 		$121K Buy
+305
New +$142K ﹤0.01% 1372
2020
Q4 		– Sell
-115
Closed -$43K – 905
2020
Q3 		$43K Buy
+115
New +$50.8K 0.01% 560

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Ergoteles's TCRT Position: Q1 2023 in Review

Ergoteles sold out of Alaunos Therapeutics (TCRT) in Q1 2023, closing a stake of 761 shares — an estimated $74.1K sold.

Ergoteles first reported a position in TCRT in Q3 2020 and held it in 6 quarters. The position peaked at $1.16M in Q2 2022. 108 funds tracked by Wall St. Rank hold TCRT as of Q1 2023.

  • Ergoteles reported no remaining Alaunos Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 761 Alaunos Therapeutics shares in Q1 2023, an estimated $74.1K.
  • Ergoteles first reported a position in Alaunos Therapeutics in Q3 2020 and held it in 6 quarters.
  • Ergoteles's Alaunos Therapeutics position peaked at $1.16M in Q2 2022.
  • 108 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.